Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2022

25.08.2022 | original report

Systemic inflammatory response index is a prognostic biomarker in unresectable pancreatic adenocarcinoma and identifies patients for more intensive treatment

verfasst von: MD Sara Dâmaso, MD Rita Paiva, MD Inês Pinho, MD Miguel Esperança-Martins, MD Raquel Lopes Brás, MD Cecília Melo Alvim, MD António Quintela, MD Ana Lúcia Costa, MD Luís Costa

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

The link between systemic inflammation and pancreatic cancer is widely accepted. The systemic inflammatory response index (SIRI), based on peripheral neutrophil, monocyte, and lymphocyte counts, emerged recently as a prognostic tool in several types of cancer. The aim of this study is to evaluate the prognostic and predictive value of baseline SIRI in unresectable pancreatic cancer.

Materials and methods

Retrospective analysis of 112 patients with unresectable pancreatic ductal adenocarcinoma (PDAC) followed between 2016 and 2021. Receiver operating characteristic (ROC) curve analysis was used to obtain the optimal SIRI cut-off value, which was set at 1.34.

Results

Univariate analysis showed that SIRI ≥ 1.34 was associated with significantly lower overall survival (OS; p < 0.0001). Multivariate analyses confirmed that SIRI is an independent prognostic factor regardless of first-line chemotherapy regimen (p < 0.0001; hazard ratio [HR] 0.363; 95% confidence interval [CI] 0.223–0.566). Also, patients with SIRI ≥ 1.34 undergoing platinum-based treatment had significantly longer OS than those treated with gemcitabine-based regimens (p = 0.002).

Conclusion

Our study suggests that SIRI is able to predict OS in patients with PDAC. Patients with high SIRI values treated with platinum-based chemotherapy achieved longer OS than those treated with gemcitabine-based regimens.
Literatur
2.
Zurück zum Zitat Costa PM, Marinho RT, Cortez-Pinto H, et al. Twenty-five years of increasing mortality from pancreatic cancer in Portugal. Pancreas. 2020;43(1):e2–e3. CrossRef Costa PM, Marinho RT, Cortez-Pinto H, et al. Twenty-five years of increasing mortality from pancreatic cancer in Portugal. Pancreas. 2020;43(1):e2–e3. CrossRef
Metadaten
Titel
Systemic inflammatory response index is a prognostic biomarker in unresectable pancreatic adenocarcinoma and identifies patients for more intensive treatment
verfasst von
MD Sara Dâmaso
MD Rita Paiva
MD Inês Pinho
MD Miguel Esperança-Martins
MD Raquel Lopes Brás
MD Cecília Melo Alvim
MD António Quintela
MD Ana Lúcia Costa
MD Luís Costa
Publikationsdatum
25.08.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00829-2